熱門資訊> 正文
Novavax允许赛诺菲将Matrix-M佐剂用于大流行流感候选疫苗
2025-09-30 21:30
- Novavax (NASDAQ:NVAX) has expanded a license agreement that will allow Sanofi (NASDAQ:SNY) to use the former's Matrix-M adjuvant for the latter's pandemic influenza vaccine program.
- Sanofi is permitted to use the adjuvant for early-stage development of the pandemic flu vaccine through phase 2. If the asset enters phase 3, the companies will negotiate license and financial terms.
- The original licensing agreement stated that Novavax could get up to $200M for the first four products developed by Sanofi utilizing Matrix-M adjuvant, as well as up to $210 million in milestone payments for each product, and ongoing royalties.
- Sanofi recently received funding from HHS' Biomedical Advanced Research and Development Authority for early-stage work on a pandemic flu vaccine.
More on Novavax
- Novavax: Endlessly Frustrating, Endlessly Fascinating - Warrants Rating Upgrade
- Novavax, Inc. (NVAX) Presents At Cantor Global Healthcare Conference 2025 Transcript
- Novavax, Inc. (NVAX) Q2 2025 Earnings Call Transcript
- CDC vaccines panel votes unanimously to change COVID-19 vaccine recommendation
- CDC vaccines panel head Kulldorff challenges former directors to debate
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
